Urogen Pharma To Present At The Guggenheim Securities Emerging Outlook: Biotech Summit

2026-02-04 08:01:30

(MENAFN- GlobeNewsWire - Nasdaq) PRINCETON, N.J., Feb. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will present at the Guggenheim Securities Emerging Outlook: Biotech Summit to take place on February 11-12, 2026.

Guggenheim Emerging Outlook: Biotech Summit 2026

Date / Time:	February 12, 2026, at 2:30 PM ET
Format:	Fireside Chat and 1x1 investor meetings
Location:	New York, NY
Webcast Link:	here

The webcast from the conference will also be available on UroGen's corporate website, under Events & Presentations. A replay will be available for approximately 90 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel^® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first commercial product is approved to treat low-grade upper tract urothelial cancer, and UroGen's second product is the first and only FDA-approved medication for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, New Jersey with operations in Israel. To learn more, visit or follow us on X (Twitter), @UroGenPharma

INVESTORS:

Vincent Perrone
Senior Director, Investor Relations
...
609-460-3588 ext. 1093

MEDIA:

Cindy Romano
Director, Corporate Communications
...
609-460-3583 ext. 1083

MENAFN04022026004107003653ID1110694526

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.